lavanya Choppavarapu | Molecular and Cellular Neuroscience | Research Excellence Award

Dr. lavanya Choppavarapu | Molecular and Cellular Neuroscience | Research Excellence Award

Dr. lavanya Choppavarapu | Medical college of Wisconsin | United States

Lavanya Choppavarapu, Ph.D., is a research scientist specializing in cancer genomics, chromatin biology, and genome-editing technologies. She currently serves at the Medical College of Wisconsin, where she leads projects applying CRISPR-Cas9 approaches to investigate mechanisms of endocrine-resistant breast cancer. Her postdoctoral training at the Medical College of Wisconsin and the University of Texas Health Science Center San Antonio strengthened her expertise in regulatory genomics, particularly in defining the roles of chromatin looping, 3D genome organization, and enhancer–promoter interactions across breast, prostate, and pancreatic cancer models. Earlier, at the National Institute of Mental Health and Neurosciences, she contributed extensively to human genetics research as a Senior and Junior Research Fellow, and further gained foundational experience at the All India Institute of Medical Sciences. Her academic background spans biotechnology and human genetics, providing a multidisciplinary foundation for her cancer-focused investigations. Dr. Choppavarapu has produced impactful scientific contributions, reflected in 189 citations, an h-index of 8, an i10-index of 7, and 132 citation counts with an h-index of 6 and i10-index of 5 across platforms. Her work continues to advance understanding of gene regulation, epigenetic control, and chromatin dynamics in cancer progression.

Profile: Google Scholar

Featured Publications

Lavanya, C., Venkataswamy, M. M., Sibin, M. K., Srinivas Bharath, M. M., Manoj, M. J., & others. (2018). Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells. Cytotechnology, 70(4), 1143–1154.

Sibin, M. K., Bhat, D. I., Narasingarao, K. V. L., Lavanya, C., & Chetan, G. K. (2015). CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. Tumor Biology, 36(10), 7607–7614.

Li, J., Fang, K., Choppavarapu, L., Yang, K., Yini, X., & others. (2021). Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance. Clinical Epigenetics, 13, Article 175.

Yang, Y., Choppavarapu, L., Fang, K., Naeini, A. S., Nosirov, B., Li, J., Yang, K., & others. (2020). The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochimica et Biophysica Acta (BBA) – Gene Regulatory Mechanisms, 1863(11), 194631.

Lavanya, C., Sibin, M. K., Srinivas Bharath, M. M., Manoj, M. J., & others. (2016). RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells. Cytotechnology, 68(6), 2311–2321.

Sibin, M. K., Bhat, D. I., Lavanya, C., Manoj, M. J., Aakershita, S., & Chetan, G. K. (2014). CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients. Tumor Biology, 35(2), 1467–1472.